Share-based Payment Arrangement, Expense of BioXcel Therapeutics, Inc. from 31 Mar 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
BioXcel Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2017 to 30 Sep 2025.
  • BioXcel Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $581,000, a 69% decline year-over-year.
  • BioXcel Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $2,118,000, a 79% decline year-over-year.
  • BioXcel Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $6,156,000, a 67% decline from 2023.
  • BioXcel Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $18,614,000, a 7.4% increase from 2022.
  • BioXcel Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $17,337,000, a 11% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

BioXcel Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $2,118,000 $581,000 -$1,284,000 -69% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $3,402,000 $1,556,000 +$499,000 +47% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $2,903,000 $180,000 -$3,253,000 -95% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $6,156,000 $199,000 -$3,798,000 -106% 01 Oct 2024 31 Dec 2024 10-K 28 Mar 2025 2024 FY
Q3 2024 $9,954,000 $1,865,000 -$2,149,000 -54% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $12,103,000 $1,057,000 -$5,067,000 -83% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $17,170,000 $3,433,000 -$1,444,000 -30% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $18,614,000 $3,599,000 -$948,000 -21% 01 Oct 2023 31 Dec 2023 10-K 28 Mar 2025 2024 FY
Q3 2023 $19,562,000 $4,014,000 -$469,000 -10% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $20,031,000 $6,124,000 +$1,642,000 +37% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $18,389,000 $4,877,000 +$1,052,000 +28% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $17,337,000 $4,547,000 +$2,312,000 +103% 01 Oct 2022 31 Dec 2022 10-K 22 Mar 2024 2023 FY
Q3 2022 $15,025,000 $4,483,000 -$403,000 -8.2% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $15,428,000 $4,482,000 -$2,287,000 -34% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $17,715,000 $3,825,000 -$1,740,000 -31% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $19,455,000 $2,235,000 -$4,376,000 -66% 01 Oct 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
Q3 2021 $23,831,000 $4,886,000 -$382,000 -7.3% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2021 2021 Q3
Q2 2021 $24,213,000 $6,769,000 +$4,813,000 +246% 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2021 2021 Q2
Q1 2021 $19,400,000 $5,565,000 +$4,789,000 +617% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2021 2021 Q1
Q4 2020 $14,611,000 $6,611,000 +$5,957,000 +911% 01 Oct 2020 31 Dec 2020 10-K 11 Mar 2022 2021 FY
Q3 2020 $8,654,000 $5,268,000 +$4,492,000 +579% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $4,162,000 $1,956,000 +$926,000 +90% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021 2021 Q2
Q1 2020 $3,236,000 $776,000 +$94,000 +14% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 $3,142,000 $654,000 +$522,000 +395% 01 Oct 2019 31 Dec 2019 10-K 12 Mar 2021 2020 FY
Q3 2019 $2,620,000 $776,000 -$114,000 -13% 01 Jul 2019 30 Sep 2019 10-Q 14 Nov 2019 2019 Q3
Q2 2019 $2,734,000 $1,030,000 +$289,000 +39% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2019 2019 Q2
Q1 2019 $2,445,000 $682,000 -$637,000 -48% 01 Jan 2019 31 Mar 2019 10-Q 12 May 2020 2020 Q1
Q4 2018 $3,082,000 $132,000 -$958,000 -88% 01 Oct 2018 31 Dec 2018 10-K 09 Mar 2020 2019 FY
Q3 2018 $4,040,000 $890,000 +$574,000 +182% 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2019 2019 Q3
Q2 2018 $3,466,000 $741,000 +$648,000 +697% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $2,818,000 $1,319,000 +$1,212,000 +1133% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q4 2017 $1,606,000 $1,090,000 01 Oct 2017 31 Dec 2017 10-K 12 Mar 2019 2018 FY
Q3 2017 $316,000 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018 2018 Q3
Q2 2017 $93,000 01 Apr 2017 30 Jun 2017 10-Q 08 Aug 2018 2018 Q2
Q1 2017 $107,000 01 Jan 2017 31 Mar 2017 10-Q 14 May 2018 2018 Q1

BioXcel Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $6,156,000 -$12,458,000 -67% 01 Jan 2024 31 Dec 2024 10-K 28 Mar 2025 2024 FY
2023 $18,614,000 +$1,277,000 +7.4% 01 Jan 2023 31 Dec 2023 10-K 28 Mar 2025 2024 FY
2022 $17,337,000 -$2,118,000 -11% 01 Jan 2022 31 Dec 2022 10-K 22 Mar 2024 2023 FY
2021 $19,455,000 +$4,844,000 +33% 01 Jan 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
2020 $14,611,000 +$11,469,000 +365% 01 Jan 2020 31 Dec 2020 10-K 11 Mar 2022 2021 FY
2019 $3,142,000 +$60,000 +1.9% 01 Jan 2019 31 Dec 2019 10-K 12 Mar 2021 2020 FY
2018 $3,082,000 +$1,476,000 +92% 01 Jan 2018 31 Dec 2018 10-K 09 Mar 2020 2019 FY
2017 $1,606,000 01 Jan 2017 31 Dec 2017 10-K 12 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.